Pcrit-DISE: Measurement of Critical Closing Pressure (Pcrit) During Drug-Induced Sleep Endoscopy (DISE)

Sponsor
University Hospital, Antwerp (Other)
Overall Status
Completed
CT.gov ID
NCT04232410
Collaborator
(none)
13
1
10.5
1.2

Study Details

Study Description

Brief Summary

This study intends to test the feasibility of measurement of the critical closing pressure (Pcrit) during drug-induced sleep endoscopy (DISE) for use in future studies, which are aimed at finding an alternative method for patient selection and response prediction before implementation of non-CPAP therapies.Twenty patients diagnosed with OSA and eligible for non-CPAP treatments are going to be included into this study and undergo these measurements. Drug-induced sleep endoscopy (DISE) is part of the standard clinical care for OSA patients that are eligible for non-CPAP therapies. We aim to expand this procedure with measurement of Pcrit, oesophageal pressure, airflow, EEG, EOG, respiratory effort, SpO2 and chin EMG during this study.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Drug induced sleep endoscopy
  • Diagnostic Test: Measurement of critical closing pressure of the uppper airway

Detailed Description

Patients from the ENT department will be recruited and informed about the study. After obtaining informed consent, the patients will undergo DISE according to the normal clinical care.The study will be performed during this clinical DISE, using a standard polysomnographic set-up (Alice 6 LDx, Philips Respironics) expanded with pressure and flow measurements. After measurements and evaluations are done, the most suitable treatment option based on the DISE and PSG findings, as defined in the standard clinical care, will be advised to the patient. The treatment and its further choice are not part of the current study protocol.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
13 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Measurement of Critical Closing Pressure (Pcrit) During Drug-Induced Sleep Endoscopy (DISE)
Actual Study Start Date :
Jan 15, 2020
Actual Primary Completion Date :
Oct 27, 2020
Actual Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
OSA Pcrit-DISE

Patients diagnosed with OSA and eligible for non-CPAP treatments

Diagnostic Test: Drug induced sleep endoscopy
DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
Other Names:
  • DISE
  • Diagnostic Test: Measurement of critical closing pressure of the uppper airway
    After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
    Other Names:
  • Pcrit measurement
  • Outcome Measures

    Primary Outcome Measures

    1. Critical closing pressure of the upper airway (Pcrit) [1 hour]

      The pressure at which the upper airway collpases measured in cm H2O.

    Secondary Outcome Measures

    1. Airflow [1 hour]

      By using a pneumotachometer attached to a transducer the inspiratory and expiratory airflow (l/s) will be measured.

    2. EEG [1 hour]

      Using electroencephalogram electrodes C3, C4, O1, F4 to evaluate sleep and wake stages and ground and system reference electrodes (volt)

    3. Esophageal pressure [1 hour]

      The pressure of the esophagus measured in cmH2O using an esophageal ballooon catheter.

    4. SpO2 [1 hour]

      using a pulse oximetry device, to non-invasively measure arterial oxygen saturation level (%).

    5. EMG [1 hour]

      Using electromyogram electrodes to evaluate muscular activity (volt)

    6. EOG [1 hour]

      electrooculogram electrodes to evaluate rapid eye movements (volt)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18 years or older

    • Diagnosis with OSA (AHI ≥15/hour sleep)

    • Eligible for DISE as the next step in the clinical path for OSA.

    • Capable of giving informed consent

    Exclusion Criteria:
    • Medication use related to sleeping disorders.

    • Central sleep apnea syndrome.

    • Medical history of known causes of tiredness or severe sleep disruption other than OSA (insomnia, PLMS, Narcolepsy).

    • Seizure disorder.

    • Known medical history of intellectual disability, memory disorders or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the patient).

    • Inability to provide informed consent.

    • Simultaneous use of other treatment modalities to treat OSA

    • Esophageal ulceration, tumors, diverticulitis, bleeding varices, sinusitis, epistaxis, recent nasopharyngeal surgery

    • Pregnancy or willing to become pregnant

    • Excessive alcohol or drug use (> 20 alcohol units/week or any use of hard drugs)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Antwerp University Hospital Edegem Antwerp Belgium 2650

    Sponsors and Collaborators

    • University Hospital, Antwerp

    Investigators

    • Study Chair: Olivier Vanderveken, MD, PhD, Head of ENT department, UZA

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    ethisch.comite@uza.be, Prof. Dr. Olivier Vanderveken, University Hospital, Antwerp
    ClinicalTrials.gov Identifier:
    NCT04232410
    Other Study ID Numbers:
    • BE300201940940
    First Posted:
    Jan 18, 2020
    Last Update Posted:
    Aug 5, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 5, 2021